FindTrial
Sign In

The role of Omega-3 polyunsaturated fatty acids in the prevention of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) in chronic kidney disease (CKD) patients

Role of Omega-3 in the prevention of contrast-induced nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016031320441N3
Enrollment
80
Registered
2016-04-29
Start date
2015-09-30
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal disease. Nephropathy induced by other drugs, medicaments and biological substances

Interventions

Intervention 1: Intervention: omega-3 12hrs before PCI plus standard CIN preventive therapy (hydration). Intervention 2: Control: just standard CIN preventive therapy (hydration).
Prevention
Intervention: omega-3 12hrs before PCI plus standard CIN preventive therapy (hydration)
Control: just standard CIN preventive therapy (hydration)

Sponsors

Vice chancellor for research, Shiraz University of Medical Sciences, International branch
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria included chronic kidney disease with GFR 15- 60 ml/min/1.73 m2, the ages of 18 to 80 years, and patients undergoing elective PCI. Exclusion criteria: Pretreatment with N-acetyl cystein or intravenous vitamin C; sensitivity or tolerance to ASA or Clopidogrel or omega-3; sever adverse effects to drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Cystatin C. Timepoint: 24 hours after PCI. Method of measurement: kit.;Serum creatinine. Timepoint: 24 hours after PCI. Method of measurement: kit.—

Secondary

MeasureTime frame
CIN occurrence. Timepoint: 24 hrs after PCI. Method of measurement: based on cystatin C.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Foroughinia

Shiraz University of Medical Sciences

farzanehforoughinia@yahoo.com00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026